標題: Titlebook: Combination Therapy In Dyslipidemia; Maciej Banach Book 2015 Springer International Publishing Switzerland 2015 Alirocumab.Anacetrapib.Apo [打印本頁] 作者: 雜技演員 時間: 2025-3-21 18:56
書目名稱Combination Therapy In Dyslipidemia影響因子(影響力)
書目名稱Combination Therapy In Dyslipidemia影響因子(影響力)學科排名
書目名稱Combination Therapy In Dyslipidemia網絡公開度
書目名稱Combination Therapy In Dyslipidemia網絡公開度學科排名
書目名稱Combination Therapy In Dyslipidemia被引頻次
書目名稱Combination Therapy In Dyslipidemia被引頻次學科排名
書目名稱Combination Therapy In Dyslipidemia年度引用
書目名稱Combination Therapy In Dyslipidemia年度引用學科排名
書目名稱Combination Therapy In Dyslipidemia讀者反饋
書目名稱Combination Therapy In Dyslipidemia讀者反饋學科排名
作者: 積云 時間: 2025-3-21 20:39
978-3-319-36721-7Springer International Publishing Switzerland 2015作者: entreat 時間: 2025-3-22 02:20 作者: fixed-joint 時間: 2025-3-22 07:27
Keynes and the Cambridge Economics Schoolding dietary plant sterols [1]. Both dietary cholesterol consumption and intestinal cholesterol absorption contribute to plasma cholesterol concentrations. Ezetimibe lowers plasma cholesterol by decreasing cholesterol absorption in the small intestine.作者: Prologue 時間: 2025-3-22 09:48 作者: 點燃 時間: 2025-3-22 15:25 作者: 點燃 時間: 2025-3-22 17:08 作者: glamor 時間: 2025-3-22 22:25 作者: laparoscopy 時間: 2025-3-23 04:44
Maciej BanachAddresses a gap left by the latest dyslipidemia management guidelines.Current and comprehensive discussion of options for combination therapy of dyslipidemia.Contributions from an internationally accl作者: 表被動 時間: 2025-3-23 08:53 作者: RACE 時間: 2025-3-23 13:26
Statins and Fibrates: Should They Be Recommended?,idual risk reducing, fibrates seem to be a very important alternative, especially for patients with atherogenic dyslipidaemia, which might be often observed in patients with diabetes and metabolic syndrome.作者: 包裹 時間: 2025-3-23 17:14 作者: 擔憂 時間: 2025-3-23 19:07
https://doi.org/10.1007/978-3-031-35955-2(LDL-C) in order to reduce risk for acute cardiovascular events in both the primary and secondary prevention settings [1–3]. There is growing consensus that when it comes to LDL-C management, lower is better with no apparent lower limit that is discernible from current evidence, i.e., there is great作者: BAIL 時間: 2025-3-24 01:50 作者: 套索 時間: 2025-3-24 02:51 作者: foliage 時間: 2025-3-24 09:59 作者: 脆弱吧 時間: 2025-3-24 13:09
https://doi.org/10.1057/9781403932860 However, despite their lipid lowering and cardioprotective effects, substantial residual cardiovascular risk persists in some patients taking statins, particularly in some subgroups, such as those with atherogenic dyslipidemia, i.e., high TG and low HDL. There has been significant controversy regar作者: antiquated 時間: 2025-3-24 15:17 作者: RECUR 時間: 2025-3-24 22:02 作者: upstart 時間: 2025-3-24 23:45
https://doi.org/10.1007/978-1-349-20920-0om birth and the occurrence of premature cardiovascular disease and myocardial infarction. ADH is determined by defects in genes encoding for proteins involved in the metabolism of LDL, including ., . and .. Carrying these mutations results in the exposure to high levels of LDL-C from birth and the 作者: 鎮(zhèn)壓 時間: 2025-3-25 04:41 作者: 決定性 時間: 2025-3-25 10:34 作者: Offstage 時間: 2025-3-25 14:20
https://doi.org/10.1057/9780230117501tage of these patients, present-day pharmacotherapy, consisting of statins alone or in combination with other lipid-modifying medications, is unable to sufficiently reduce plasma cholesterol levels..Since the late 1970s, simple plasma exchange or the more selective lipoprotein apheresis (LA) therapy作者: 珠寶 時間: 2025-3-25 17:01 作者: neutrophils 時間: 2025-3-25 20:00
Bembibre to Cacabelos and Villafranca,ed “a strategy to reduce cardiovascular disease by more than 80 %” by simultaneously addressing four cardiovascular risk factors regardless of pretreatment levels in a low-risk population. They stated, “the polypill strategy could largely prevent heart attacks and strokes if taken by everyone aged 5作者: filicide 時間: 2025-3-26 01:23 作者: 諂媚于性 時間: 2025-3-26 04:50 作者: 震驚 時間: 2025-3-26 08:58
Book 2015d sequestrants, fibric acid derivatives (fibrates), omega-3 fatty acids (fish oils), inhibitors of Niemann-Pick C1 like 1 (NPC1L1) protein, cholesteryl ester transfer protein (CETP), apolipoprotein B-100 and microsomal triglyceride transfer protein (MTP) and the emerging proprotein convertase subtil作者: 厭煩 時間: 2025-3-26 15:46 作者: watertight, 時間: 2025-3-26 18:54 作者: Costume 時間: 2025-3-26 23:37
https://doi.org/10.1057/9781403932860or prevention of adverse cardiovascular outcomes and treatment of derangements in lipid serologies. Current guidelines and recommendations support their regular integration into the diet and supplementation for those with severe hypertriglyceridemia as adjunct therapy. Emerging data suggests that OM作者: occurrence 時間: 2025-3-27 02:08 作者: MAZE 時間: 2025-3-27 06:51
https://doi.org/10.1007/978-1-349-20920-0rol-lowering drugs, especially subjects carrying mutations that drastically reduce the expression of hepatic LDLR. Thus, the need to find out new drugs directed to different targets led to the development of lomitapide, an inhibitor of microsomal triglyceride transfer protein (MTP), an enzyme playin作者: 與野獸博斗者 時間: 2025-3-27 09:46
A Condition of England Minister,al trials have shown that these nutraceuticals have an additive effect to statins, allowing to reduce the doses of statins without decreasing the results in terms of effectiveness in reducing total and LDL-cholesterol and significantly limiting side effects..The results of the studies carried out ha作者: 態(tài)度暖昧 時間: 2025-3-27 15:29 作者: evanescent 時間: 2025-3-27 20:16
The History of the East India Company II: ,,he practical issues of combined antihypertensive and lipid-lowering therapy, including adherence, cost-effectiveness, and effect of complementary therapy as well as the future of integrated management.作者: follicular-unit 時間: 2025-3-27 22:11 作者: 天賦 時間: 2025-3-28 02:48 作者: esculent 時間: 2025-3-28 06:21
Statins and Niacin: The End of Residual Risk Therapy?,se in serious adverse effects. More specifically, apart from flushing, niacin was associated with increased incidence of new-onset diabetes and with a higher risk of all-cause mortality. As a result, niacin is no longer on the market in many countries.作者: anarchist 時間: 2025-3-28 11:20
The Role of Omega-3 Fatty Acids in Dyslipidemias,or prevention of adverse cardiovascular outcomes and treatment of derangements in lipid serologies. Current guidelines and recommendations support their regular integration into the diet and supplementation for those with severe hypertriglyceridemia as adjunct therapy. Emerging data suggests that OM作者: CLOWN 時間: 2025-3-28 15:37 作者: 激勵 時間: 2025-3-28 19:39
Statins and Lomitapide: A Suitable Response for Homozygous Familial Hypercholesterolemia?,rol-lowering drugs, especially subjects carrying mutations that drastically reduce the expression of hepatic LDLR. Thus, the need to find out new drugs directed to different targets led to the development of lomitapide, an inhibitor of microsomal triglyceride transfer protein (MTP), an enzyme playin作者: Jubilation 時間: 2025-3-29 00:46
Statins and Nutraceuticals/Functional Food: Could They Be Combined?,al trials have shown that these nutraceuticals have an additive effect to statins, allowing to reduce the doses of statins without decreasing the results in terms of effectiveness in reducing total and LDL-cholesterol and significantly limiting side effects..The results of the studies carried out ha作者: 無聊的人 時間: 2025-3-29 03:39
Lipid-Lowering Therapy and Apheresis: Indications and Outcomes,ks depending on the severity of the patient’s disease and lipoprotein levels. Adverse reactions, though rare, are typical for other apheresis procedures. Due to the sophistication of the procedure, cost, and time commitment, presently only about 3,000 patients worldwide and 550 patients in North Ame作者: Climate 時間: 2025-3-29 08:00 作者: aptitude 時間: 2025-3-29 15:26
The Cardiovascular Polypill in the Prevention of Cardiovascular Disease,sease. It was argued that a large proportion of the population would be medicalized unnecessarily, inducing a sense of protection and deflecting attention from healthy behaviors. Although this strategy raised high hopes that a polypill-based treatment could reduce the incidence of atherosclerotic ca作者: 紳士 時間: 2025-3-29 19:22 作者: decode 時間: 2025-3-29 23:08 作者: 高貴領導 時間: 2025-3-30 01:13 作者: 虛弱 時間: 2025-3-30 05:58 作者: Condense 時間: 2025-3-30 11:30 作者: 知道 時間: 2025-3-30 14:35 作者: aviator 時間: 2025-3-30 16:52 作者: 碳水化合物 時間: 2025-3-30 22:22
Statins and Mipomersen: Mechanisms of Action and Patient Tolerability,gnificant challenge, particularly in severe, inherited hypercholesterolaemia. High-intensity statin therapy can be associated with adverse outcomes, most notably myalgia, and does not frequently result in the attainment of therapeutic levels of low-density lipoprotein (LDL) cholesterol and apolipopr作者: Injunction 時間: 2025-3-31 01:12 作者: 侵略者 時間: 2025-3-31 05:06
Other Possible Drug Combinations for Dyslipidemia,ts have been successfully developed and introduced for LDL-C lowering, ezetimibe as a cholesterol absorption inhibitor being the exception [1]. Other promising lipid lowering agents such as fibrates and niacin have failed to provide mortality benefits in large clinical trials and are only used in se作者: garrulous 時間: 2025-3-31 13:09
Statins and Nutraceuticals/Functional Food: Could They Be Combined?,of the leading causes of death in developed countries..Therefore, an effective treatment to reduce high cholesterol is necessary: statins have proved to be the gold standard among lipid-lowering drugs, but at the cost of many unpleasant side effects..At the same time, many nutraceuticals or function作者: 洞察力 時間: 2025-3-31 14:59 作者: Basal-Ganglia 時間: 2025-3-31 19:27
Combination of Lipid-Lowering Agents with Antihypertensive Drugs: A Joint Fight Against the Two Mosa is common, particularly among older persons and those with diabetes and cardiovascular disease (CVD). When hypertension is accompanied by dyslipidemia, the combined risk for future CVD is substantial. Therefore, many studies have examined the effect of combined therapy for hypertension and dyslipi作者: OTHER 時間: 2025-3-31 23:55